Titan Pharmaceuticals, Inc.: profit or loss including noncontrolling interests

What this measure means

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Exact concept: us-gaap:ProfitLoss. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2021-01-01 to 2024-12-31. The SEC response was captured on 2026-09-21.

Selected filing history

Related financial histories

• Titan Pharmaceuticals, Inc.: total assets
• Titan Pharmaceuticals, Inc.: total liabilities
• Titan Pharmaceuticals, Inc.: stockholders equity
• Titan Pharmaceuticals, Inc.: cash and cash equivalents
• Titan Pharmaceuticals, Inc.: net income or loss
• Titan Pharmaceuticals, Inc.: operating cash flow
• Titan Pharmaceuticals, Inc.: capital expenditure payments
• Titan Pharmaceuticals, Inc.: revenue
• Titan Pharmaceuticals, Inc.: financing cash flow
• Titan Pharmaceuticals, Inc.: investing cash flow
• Titan Pharmaceuticals, Inc.: retained earnings or deficit
• Titan Pharmaceuticals, Inc.: basic weighted-average shares
• Titan Pharmaceuticals, Inc.: diluted weighted-average shares
• Titan Pharmaceuticals, Inc.: basic earnings per share
• Titan Pharmaceuticals, Inc.: diluted earnings per share
• Titan Pharmaceuticals, Inc.: income tax expense or benefit
• Titan Pharmaceuticals, Inc.: net property, plant and equipment
• Titan Pharmaceuticals, Inc.: share-based compensation expense
• Titan Pharmaceuticals, Inc.: operating income or loss
• Titan Pharmaceuticals, Inc.: current assets
• Titan Pharmaceuticals, Inc.: current liabilities
• Titan Pharmaceuticals, Inc.: current accounts payable
• Titan Pharmaceuticals, Inc.: net current accounts receivable
• Titan Pharmaceuticals, Inc.: operating expenses
• Titan Pharmaceuticals, Inc.: net inventory
• Titan Pharmaceuticals, Inc.: selling, general and administrative expense
• Titan Pharmaceuticals, Inc.: research and development expense
• Titan Pharmaceuticals, Inc.: common shares outstanding
• Titan Pharmaceuticals, Inc.: cash including restricted cash
• Titan Pharmaceuticals, Inc.: additional paid-in capital
• Titan Pharmaceuticals, Inc.: operating lease right-of-use asset
• Titan Pharmaceuticals, Inc.: operating lease liability
• Titan Pharmaceuticals, Inc.: gross property, plant and equipment
• Titan Pharmaceuticals, Inc.: accumulated depreciation on property, plant and equipment
• Titan Pharmaceuticals, Inc.: other noncurrent assets
• Titan Pharmaceuticals, Inc.: accrued current liabilities
• Titan Pharmaceuticals, Inc.: prepaid expenses and other current assets
• Titan Pharmaceuticals, Inc.: comprehensive income or loss
• Titan Pharmaceuticals, Inc.: net income available to common stockholders
• Titan Pharmaceuticals, Inc.: general and administrative expense
• Titan Pharmaceuticals, Inc.: depreciation, depletion and amortization
• Titan Pharmaceuticals, Inc.: other nonoperating income or expense
• Titan Pharmaceuticals, Inc.: nonoperating income or expense
• Titan Pharmaceuticals, Inc.: interest paid, net
• Titan Pharmaceuticals, Inc.: change in accounts receivable
• Titan Pharmaceuticals, Inc.: change in inventories

Inspect the source

Entity

Titan Pharmaceuticals, Inc. / CIK 0000910267

Captured

2026-09-21T17:17:21.539Z

SEC response SHA-256

452f10f2ccebf3c2fc56928a34e465f1e463941958497d363e8fdef6c3b42dd1

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000910267.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))